Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
BIOVERATIV INC COMMON (BIVV)
Last bioverativ inc common earnings: 2/13 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bioverativ.com/phoenix.zhtml?c=254463&p=irol-irhome_pf
Company Research
Source: Business Wire
Significant unmet need for a treatment for cold agglutinin disease, a chronic rare blood disease that can result in life-threatening events like stroke BIVV009 granted breakthrough therapy designation by the FDA in May 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced that the first patient has been dosed in the Phase 3 clinical program of its investigational therapy BIVV009 for cold agglutinin disease (CAgD). The Phase 3 program includes two parallel Phase 3 trials, Cardinal and Cadenza, which are evaluating the efficacy and safety of BIVV009 in adult patients with primary CAgD, a disease with no approved therapies. CAgD is a rare blood disease that results in the premature destruction of red blood cells (hemo
Show less
Read more
Impact Snapshot
Event Time:
BIVV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIVV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIVV alerts
High impacting BIOVERATIV INC COMMON news events
Weekly update
A roundup of the hottest topics